BIIB Stock Recent News

BIIB LATEST HEADLINES

BIIB Stock News Image - zacks.com

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

zacks.com 2025 Jul 28
BIIB Stock News Image - globenewswire.com

CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment which was approved by the U.S. Food and Drug Administration (FDA) in 2023.

globenewswire.com 2025 Jul 25
BIIB Stock News Image - zacks.com

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com 2025 Jul 24
BIIB Stock News Image - globenewswire.com

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

globenewswire.com 2025 Jul 21
BIIB Stock News Image - benzinga.com

Biogen Inc.  BIIB said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP).

benzinga.com 2025 Jul 21
BIIB Stock News Image - reuters.com

Drugmaker Biogen said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.

reuters.com 2025 Jul 21
BIIB Stock News Image - globenewswire.com

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP). Since breaking ground in 1995, Biogen's manufacturing in RTP has played a vital role in delivering the company's pipeline and portfolio of innovative treatments for millions of patients around the world. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen's late-stage clinical pipeline.

globenewswire.com 2025 Jul 21
BIIB Stock News Image - globenewswire.com

– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass.

globenewswire.com 2025 Jul 10
BIIB Stock News Image - businesswire.com

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a.

businesswire.com 2025 Jul 10
BIIB Stock News Image - zacks.com

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

zacks.com 2025 Jul 01
10 of 50